Professional
Added to YB: 2025-06-11
Pitch date: 2025-06-09
GRAL [bearish]
GRAIL, Inc.
-128.17%
current return
Author Info
NINGI Research publishes research reports and notes on publicly traded companies in the US and Europe. The research is sector-agnostic and tends to be focused on forensic accounting. Sign up for the newsletter.
Company Info
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally.
Market Cap
$3.1B
Pitch Price
$39.90
Price Target
14.28 (-84%)
Dividend
N/A
EV/EBITDA
-7.92
P/E
-6.85
EV/Sales
18.49
Sector
Biotechnology
Category
special_situation
GRAIL (NASDAQ: GRAL): Why Galleri Will Fail the Real Test: Regulatory Approval and Widespread Commercialization All But Impossible
GRAL short: Galleri cancer test lacks clinical mortality data required for FDA approval, insurance coverage, & reimbursement. 43.1% PPV misleading vs. real-world performance. Management ignores expert feedback amid lawsuits, toxic culture. MCED legislation won't save a cash-burning company with no viable commercialization path. Fair value: $14.28/share.
Read full article (2 min)